anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

164,761-164,820 of 319,975

filter-aware
01
Slide 1
Features company logo and date.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank 1 hit
02
TScan Therapeutics | IPO Presentation Deck | 43 slidesTScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank 1 hit
03
TScan Therapeutics | IPO Presentation Deck | 43 slidesTScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank 1 hit
04
The slide uses a stylized 'T' graphic with a timeline-like bullet structure.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank 1 hit
05
The slide uses a grid layout to present 12 team members with headshots, names, titles, and logos of past/associated organizations.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · Team1 hit
06
The slide uses a process flow to explain the 'Learning' phase of their technology platform.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
07
The slide title is likely a continuation from a previous slide (e.g., '...to treat patients who are not eligible for standard therapies').TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
08
Uses a before-after-bridge style logic to illustrate the clinical advantage of multiplexing.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
09
The slide uses a Gantt-style visualization to show the current development stage of multiple drug candidates.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
10
The slide uses a color-coded legend to distinguish between liquid and solid tumor programs.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
11
TScan Therapeutics | IPO Presentation Deck | 43 slidesTScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
12
Uses a before-after-bridge framework to contrast current therapy limitations with TScan's solution.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
13
The slide uses a process flow diagram to explain a proprietary biotechnology platform.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
14
The slide uses a Venn diagram to explain the scope of their target discovery platform.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
15
The chart demonstrates the specificity of the TargetScan platform by highlighting MAGE-A3 as the primary target with significantly higher fold-enrichment.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
16
The chart displays fold-enrichment vs protein fragment number, identifying specific gene targets.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
17
The slide illustrates a dual-platform approach to TCR discovery and validation.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
18
The slide uses a flow-chart style diagram to position TScan's technology as an evolution of current standard-of-care cell therapies.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
19
TScan Therapeutics | IPO Presentation Deck | 43 slidesTScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · SolutionLoop · Golden Circle1 hit
20
Uses a Who/Why/When framework to define the market opportunity.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
21
The chart shows a clear upward trend in HCT procedures from 2000 to 2018, segmented by indication (AML, MDS, ALL).TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
22
Uses a process flow diagram to show the patient journey and the specific point of failure (relapse).TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
23
The slide uses a circular process flow to show the interaction between the patient's condition and the donor-derived TCR therapy.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank 1 hit
24
The slide shows three distinct charts: a time-course line graph, a bar chart for survival at 90 hours, and a bar chart comparing cell viability across different HA-1 genotypes in AML and ALL cell lines.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · Traction1 hit
25
The slide uses microscopy imagery to demonstrate therapeutic efficacy.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · Traction1 hit
26
The chart shows a scatter plot where the vast majority of data points are at zero, indicating no off-target binding.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · Traction1 hit
27
The slide uses a process flow to explain patient stratification for a clinical trial.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · Traction1 hit
28
TScan Therapeutics | IPO Presentation Deck | 43 slidesTScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · Traction1 hit
29
Uses a Venn diagram to show overlap in Head & Neck cancers, and a central 'ImmunoBank' repository feeding into multiplexed TCR-T arms.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · Traction1 hit
30
The slide highlights target expression overlap to justify multiplexed therapy.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · Traction1 hit
31
The chart shows fold-enrichment of protein fragments, highlighting a 'Novel Head & Neck Target' alongside positive controls.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · Traction1 hit
32
The chart shows fold-enrichment of protein fragments, highlighting three specific targets identified from patient data.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · Traction1 hit
33
The chart uses a log scale on the y-axis to compare expression levels across multiple tissue types.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · Traction1 hit
34
Slide 34 from TScan Therapeutics deck.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · Traction1 hit
35
The slide uses a process flow to demonstrate the company's R&D pipeline progress.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank Beat · Traction1 hit
36
The slide uses a process flow to explain the mechanism of action for the company's platform.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank 1 hit
37
TScan Therapeutics | IPO Presentation Deck | 43 slidesTScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank 1 hit
38
The slide uses a diagram to illustrate the mechanism of the T-Integrate system (transposon/transposase integration into T cell DNA).TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank 1 hit
39
TScan Therapeutics | IPO Presentation Deck | 43 slidesTScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank 1 hit
40
Uses a honeycomb/hexagonal diagram to represent the three focus areas.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank 1 hit
41
The slide highlights a specific partnership deal structure.TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank 1 hit
42
The slide uses a hexagonal diagram to represent disease areas (Oncology, Infectious Disease, Autoimmune Disease).TScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank 1 hit
43
TScan Therapeutics | IPO Presentation Deck | 43 slidesTScan Therapeutics | IPO Presentation Deck | 43 slides · TScan Therapeutics
Pitch deck Investment bank 1 hit
01
Slide 1
UBS | Results Presentation Deck | 27 slidesUBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · Attention1 hit
02
UBS | Results Presentation Deck | 27 slidesUBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · Attention1 hit
03
UBS | Results Presentation Deck | 27 slidesUBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · Attention1 hit
04
UBS | Results Presentation Deck | 27 slidesUBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · Attention1 hit
05
The slide uses a combination of bar charts for period-over-period comparison and circular callouts for net new growth metrics.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · NeedLoop · Logic Chain1 hit
06
The slide uses a combination of bar charts for historical comparison and big-number metrics for recent period performance.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · NeedLoop · Logic Chain1 hit
07
The slide uses a waterfall-style bridge to show total invested assets growth from 30.6.20 to 30.6.21.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · NeedLoop · Logic Chain1 hit
08
The table uses a grouped layout by business unit with specific columns for period-over-period comparison and target/guidance benchmarks.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · NeedLoop · Logic Chain1 hit
09
Waterfall chart shows the bridge from 2Q20 to 2Q21 profit before tax.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · SatisfactionLoop · Logic Chain1 hit
10
The chart illustrates the movement from 11.7bn to 12.8bn in operating expenses.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · SatisfactionLoop · Logic Chain1 hit
11
The slide highlights 2Q21 performance metrics compared to historical trends.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · SatisfactionLoop · Logic Chain1 hit
12
Includes a waterfall-style comparison of growth between 2Q20 and 2Q21.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · SatisfactionLoop · Logic Chain1 hit
13
Includes footnote regarding 4Q19 asset/loan shift.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · SatisfactionLoop · Logic Chain1 hit
14
The slide uses a stacked bar chart to show asset composition over time, with a callout box summarizing recent NNFGA performance and margin drivers.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · SatisfactionLoop · Logic Chain1 hit
15
Waterfall-style comparison of PBT and Operating Income components over five quarters.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · SatisfactionLoop · Logic Chain1 hit
16
The slide uses a waterfall-bridge style visualization to show the impact of the Fondcenter sale on PBT and Operating income.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations Beat · SatisfactionLoop · Logic Chain1 hit
17
Includes a breakdown of Global Markets and Global Banking revenues, plus key metrics like RoAE, RWA, and LRD.UBS | Results Presentation Deck | 27 slides · UBS
Conference presentation Investor relations 1 hit